CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
Vaccines · 19.06.2025 · 13 (6) · 654
DOI: 10.3390/vaccines13060654 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 19.06.2025. Verfasst von Yunjia Xian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-engineered cell therapy represents a landmark advancement in cancer immunotherapy. While αβ CAR-T therapy has demonstrated remarkable success in hematological malignancies, its efficacy in solid tumors remains constrained mainly by factors such as antigen heterogeneity, immunosuppressive microenvironments, and on-target/off-tumor toxicity. To overcome these limitations, emerging CAR platforms that utilize alternative immune effectors, including natural killer (NK) cells, macrophages, and γδ T lymphocytes, are rapidly gaining traction. This review systematically analyzes the mechanistic advantages of CAR-NK, CAR-M, and CAR-γδ T cell therapies, while critically evaluating persistent challenges in clinical translation, including limited cell persistence, manufacturing scalability, and dynamic immune evasion mechanisms. We further discuss innovative strategies to enhance therapeutic efficacy through some viable strategies. By bridging fundamental immunology with translational engineering, this work provides a roadmap for developing CAR therapies capable of addressing the complexities of solid tumor eradication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Hubei Key Laboratory of Precision Radiation Oncology, Wuhan 430022, China.
- Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
ORCID-Profile: Yunjia Xian
Zitieren
APA
Xian, Y., & Wen, L. (2025). CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors. Vaccines, 13(6), 654. https://doi.org/10.3390/vaccines13060654
Vancouver
Xian Y, Wen L. CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors. Vaccines. 2025;13(6):654. doi:10.3390/vaccines13060654
BibTeX
@article{Xian2025,
author = {Xian, Yunjia and Wen, Lu},
title = {CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {6},
pages = {654},
doi = {10.3390/vaccines13060654}
}
EUVIMED